Your browser doesn't support javascript.
loading
Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants.
Haycroft, Ebene R; Davis, Samantha K; Ramanathan, Pradhipa; Lopez, Ester; Purcell, Ruth A; Tan, Li Lynn; Pymm, Phillip; Wines, Bruce D; Hogarth, P Mark; Wheatley, Adam K; Juno, Jennifer A; Redmond, Samuel J; Gherardin, Nicholas A; Godfrey, Dale I; Tham, Wai-Hong; Selva, Kevin John; Kent, Stephen J; Chung, Amy W.
Afiliación
  • Haycroft ER; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, 3000, Australia.
  • Davis SK; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, 3000, Australia.
  • Ramanathan P; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, 3000, Australia.
  • Lopez E; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, 3000, Australia.
  • Purcell RA; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, 3000, Australia.
  • Tan LL; The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC, Australia.
  • Pymm P; The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC, Australia.
  • Wines BD; Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
  • Hogarth PM; Immune Therapies Group, Burnet Institute, Melbourne, VIC, Australia.
  • Wheatley AK; Department of Clinical Pathology, University of Melbourne, Melbourne, VIC, Australia.
  • Juno JA; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Redmond SJ; Immune Therapies Group, Burnet Institute, Melbourne, VIC, Australia.
  • Gherardin NA; Department of Clinical Pathology, University of Melbourne, Melbourne, VIC, Australia.
  • Godfrey DI; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Tham WH; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, 3000, Australia.
  • Selva KJ; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, 3000, Australia.
  • Kent SJ; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, 3000, Australia.
  • Chung AW; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, 3000, Australia.
Med Microbiol Immunol ; 212(4): 291-305, 2023 Aug.
Article en En | MEDLINE | ID: mdl-37477828
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Revista: Med Microbiol Immunol Año: 2023 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Revista: Med Microbiol Immunol Año: 2023 Tipo del documento: Article País de afiliación: Australia